See more : Clontarf Energy plc (CLON.L) Income Statement Analysis – Financial Results
Complete financial analysis of DBV Technologies S.A. (DBVT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of DBV Technologies S.A., a leading company in the Biotechnology industry within the Healthcare sector.
- Impac Mortgage Holdings, Inc. (IMPHO) Income Statement Analysis – Financial Results
- People, Dreams & Technologies Group Co., Ltd. (9248.T) Income Statement Analysis – Financial Results
- GH Research PLC (GHRS) Income Statement Analysis – Financial Results
- Rocket Internet Growth Opportunities Corp. (RKTA) Income Statement Analysis – Financial Results
- Nebius Group N.V. (NBIS) Income Statement Analysis – Financial Results
DBV Technologies S.A. (DBVT)
About DBV Technologies S.A.
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The milk-induced company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA); Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordetella pertussis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 15.73M | 4.80M | 5.71M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 240.98K | 332.67K | 333.43K | 297.52K | 213.05K |
| Cost of Revenue | 0.00 | 20.30M | 9.27M | 18.82M | 3.09M | 5.03M | 3.43M | 1.42M | 152.70K | 215.14K | 187.74K | 141.55K | 109.96K |
| Gross Profit | 15.73M | -15.50M | -3.57M | -18.82M | -3.09M | -5.03M | -3.43M | -1.42M | 88.28K | 117.54K | 145.69K | 155.96K | 103.09K |
| Gross Profit Ratio | 100.00% | -322.90% | -62.46% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 36.63% | 35.33% | 43.69% | 52.42% | 48.39% |
| Research & Development | 60.22M | 75.50M | 70.34M | 124.61M | 129.00M | 146.49M | 148.13M | 86.96M | 40.84M | 33.37M | 31.85M | 19.76M | 11.28M |
| General & Administrative | 25.16M | 24.30M | 30.52M | 41.87M | 55.77M | 54.23M | 49.85M | 38.42M | 20.03M | 12.81M | 11.57M | 7.88M | 4.05M |
| Selling & Marketing | -2.28M | 1.60M | 4.39M | 12.12M | 24.07M | 43.97M | 22.27M | 12.45M | 585.76K | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 22.88M | 25.90M | 34.91M | 53.98M | 79.85M | 98.20M | 72.13M | 50.86M | 20.61M | 12.81M | 11.57M | 7.88M | 4.05M |
| Other Expenses | 0.00 | 0.00 | 0.00 | -12.67M | -16.04M | -17.52M | -16.17M | -9.82M | -7.03M | -7.18M | -6.68M | -4.44M | -2.95M |
| Operating Expenses | 92.16M | 101.40M | 105.24M | 165.92M | 192.80M | 227.17M | 204.08M | 128.00M | 54.43M | 39.00M | 36.74M | 23.20M | 12.38M |
| Cost & Expenses | 92.16M | 101.40M | 105.24M | 165.92M | 192.80M | 227.17M | 204.08M | 128.00M | 54.58M | 39.22M | 36.93M | 23.34M | 12.49M |
| Interest Income | 3.78M | 406.29K | 440.79K | 0.00 | 85.15K | 673.86K | 867.09K | 1.67M | 1.21M | 1.15M | 1.23M | 883.09K | 105.44K |
| Interest Expense | 0.00 | 427.00K | 583.77K | 887.89K | 1.79M | 479.76K | 4.68M | 17.65K | 174.18K | 162.96K | 44.59K | 43.01K | 72.00K |
| Depreciation & Amortization | -4.57M | 20.30M | 9.27M | 18.82M | 3.09M | 5.03M | 3.43M | 1.42M | 1.28M | 813.52K | 625.73K | 480.40K | 288.18K |
| EBITDA | -87.46M | -76.68M | -79.77M | -162.74M | -181.37M | -206.16M | -176.90M | -126.29M | -53.62M | -36.00M | -29.56M | -21.68M | -11.88M |
| EBITDA Ratio | -556.11% | -2,012.50% | -1,759.90% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -21,512.88% | -11,099.55% | -10,418.58% | -7,286.80% | -5,575.59% |
| Operating Income | -76.43M | -96.63M | -98.61M | -194.80M | -192.80M | -227.17M | -204.08M | -128.00M | -54.34M | -38.89M | -36.59M | -23.04M | -12.27M |
| Operating Income Ratio | -485.97% | -2,013.15% | -1,727.65% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -22,547.53% | -11,689.15% | -10,974.91% | -7,745.10% | -5,760.35% |
| Total Other Income/Expenses | 3.71M | 431.00K | 8.99M | -24.67M | 9.20M | 15.56M | 19.85M | 1.66M | 1.04M | 986.34K | 1.19M | 840.08K | 33.44K |
| Income Before Tax | -72.72M | -96.20M | -98.19M | -195.69M | -194.51M | -226.98M | -207.90M | -126.35M | -53.30M | -37.90M | -35.41M | -22.20M | -12.24M |
| Income Before Tax Ratio | -462.35% | -2,004.17% | -1,720.22% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -22,116.35% | -11,393.08% | -10,619.61% | -7,462.73% | -5,744.65% |
| Income Tax Expense | 7.00K | 100.00K | -381.00K | -12.26K | 692.67K | 20.50K | 1.41K | 1.67M | 1.21M | 1.15M | 1.23M | 883.08K | 105.44K |
| Net Income | -72.73M | -96.30M | -97.81M | -195.68M | -195.20M | -227.00M | -207.90M | -126.35M | -53.30M | -37.90M | -35.41M | -22.20M | -12.24M |
| Net Income Ratio | -462.40% | -2,006.25% | -1,713.54% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -22,115.85% | -11,393.08% | -10,619.61% | -7,462.73% | -5,744.65% |
| EPS | -2.84 | -4.96 | -7.12 | -14.48 | -21.12 | -31.40 | -33.60 | -20.68 | -9.92 | -9.44 | -10.40 | -7.24 | -3.65 |
| EPS Diluted | -2.84 | -4.96 | -7.12 | -14.48 | -21.12 | -31.40 | -33.60 | -20.68 | -9.92 | -9.44 | -10.40 | -7.24 | -3.65 |
| Weighted Avg Shares Out | 23.78M | 19.35M | 13.77M | 13.52M | 9.25M | 7.23M | 6.18M | 6.11M | 5.37M | 4.02M | 3.40M | 3.07M | 3.35M |
| Weighted Avg Shares Out (Dil) | 23.78M | 19.35M | 13.77M | 13.52M | 9.25M | 7.23M | 6.19M | 6.11M | 5.38M | 4.02M | 3.40M | 3.08M | 3.35M |
DBV Technologies to Report First Half 2021 Financial Results and Business Updates on August 2, 2021
DBV Technologies to Present at Upcoming Investor Conferences
DBV Technologies Announces Filing of its First Form 10-Q for the First Quarter of 2021
DBV Technologies Reports Q1 2021 Financial Results
DBV Technologies to Participate in Upcoming Investor Conferences
Ordinary and Extraordinary General Meeting of May 19, 2021 to be Held in Closed Virtual Session Due to COVID-19 Pandemic
DBV Technologies Announces Appointment of Timothy E. Morris to Board of Directors
Monthly information regarding the total number of voting rights and total number of shares of the Company as of March 31, 2021
DBV Technologies Announces a New Chair of its Audit Committee and Date of its Annual General Meeting
Source: https://incomestatements.info
Category: Stock Reports